The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice
Open Access
- 1 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Alzheimer's Research & Therapy
- Vol. 5 (3), 25
- https://doi.org/10.1186/alzrt179
Abstract
Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has generally relied on testing compounds before pathology is present, thereby modeling disease prevention rather than disease modification. Furthermore, this approach to screening does not reflect the clinical presentation of AD patients which could explain the failure to translate compounds identified as beneficial in animal models to disease modifying compounds in clinical trials. Clearly a better approach to pre-clinical drug screening for AD is required.Keywords
This publication has 122 references indexed in Scilit:
- Episodic memory on the path to Alzheimer's diseaseCurrent Opinion in Neurobiology, 2011
- The cholinergic system in aging and neuronal degenerationBehavioural Brain Research, 2011
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm ShiftNeuron, 2011
- Neural mechanisms of ageing and cognitive declineNature, 2010
- Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophreniaPharmacology & Therapeutics, 2009
- The molecular and cellular biology of enhanced cognitionNature Reviews Neuroscience, 2009
- Anxiety in dementia: A critical reviewClinical Psychology Review, 2008
- Egr3, a synaptic activity regulated transcription factor that is essential for learning and memoryMolecular and Cellular Neuroscience, 2007
- Morris water maze: procedures for assessing spatial and related forms of learning and memoryNature Protocols, 2006
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004